184 related articles for article (PubMed ID: 30848689)
1. Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.
Skrombolas D; Sullivan M; Frelinger JG
J Interferon Cytokine Res; 2019 Apr; 39(4):233-245. PubMed ID: 30848689
[TBL] [Abstract][Full Text] [Related]
2. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.
Puskas J; Skrombolas D; Sedlacek A; Lord E; Sullivan M; Frelinger J
Immunology; 2011 Jun; 133(2):206-20. PubMed ID: 21426339
[TBL] [Abstract][Full Text] [Related]
3. A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms.
Norville K; Skrombolas D; Ferry SL; Kearns N; Frelinger JG
J Interferon Cytokine Res; 2022 Jul; 42(7):316-328. PubMed ID: 35834651
[TBL] [Abstract][Full Text] [Related]
4. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization.
Lees CJ; Apostolopoulos V; McKenzie IF
J Interferon Cytokine Res; 1999 Dec; 19(12):1373-9. PubMed ID: 10638706
[TBL] [Abstract][Full Text] [Related]
5. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
6. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
7. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
8. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus.
Anderson R; Macdonald I; Corbett T; Hacking G; Lowdell MW; Prentice HG
Hum Gene Ther; 1997 Jun; 8(9):1125-35. PubMed ID: 9189770
[TBL] [Abstract][Full Text] [Related]
9. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.
Skrombolas D; Wylie I; Maharaj S; Frelinger JG
J Interferon Cytokine Res; 2015 Sep; 35(9):690-7. PubMed ID: 25938719
[TBL] [Abstract][Full Text] [Related]
12. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors.
Li J; Hu P; Khawli LA; Yun A; Epstein AL
Hybrid Hybridomics; 2004 Feb; 23(1):1-10. PubMed ID: 15000842
[TBL] [Abstract][Full Text] [Related]
13. Gelatinase B/matrix metalloproteinase-9 and other neutrophil proteases switch off interleukin-2 activity.
Rybakin V; Stas M; Ugarte-Berzal E; Noppen S; Vandooren J; Van Aelst I; Liekens S; Proost P; Opdenakker G
Biochem J; 2019 Aug; 476(15):2191-2208. PubMed ID: 31262730
[TBL] [Abstract][Full Text] [Related]
14. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis.
El-Shabrawi YG; Christen WG; Foster SC
Curr Eye Res; 2000 Mar; 20(3):211-4. PubMed ID: 10694897
[TBL] [Abstract][Full Text] [Related]
15. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.
Stallmach A; Marth T; Weiss B; Wittig BM; Hombach A; Schmidt C; Neurath M; Zeitz M; Zeuzem S; Abken H
Gut; 2004 Mar; 53(3):339-45. PubMed ID: 14960512
[TBL] [Abstract][Full Text] [Related]
16. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
[TBL] [Abstract][Full Text] [Related]
17. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
18. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
19. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
20. Activation of matrix metalloproteinases 2, 9, and 13 by activated protein C in human osteoarthritic cartilage chondrocytes.
Jackson MT; Moradi B; Smith MM; Jackson CJ; Little CB
Arthritis Rheumatol; 2014 Jun; 66(6):1525-36. PubMed ID: 24574263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
